MedTrace Logo

Vaccination Nudges From Pharmacists

NCT07161739 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2026-02-10

No results posted yet for this study

Summary

The goal of this individual-level pragmatic randomized policy trial is to learn about the impact of behavioural nudges via mailed letters on increasing influenza and travel vaccination uptake in Alberta, Canada. The primary outcome is the proportion of adults receiving influenza and/or travel vaccination. The secondary outcome is the number of stroke events in the 6 months following vaccination. As such, this research aims to answer two key questions:

1. Do behavioural nudges increase influenza and travel vaccination in Alberta?
2. If yes, is there a decrease in the number of stroke events in the 6 months following vaccination?

The two-arm individual level pragmatic randomized trial design includes two letter dimensions, a letter (a "nudge") with an influenza and cardiovascular risk reduction message and a letter with a travel vaccination benefit message, yielding the following groups:

Letter with an influenza and cardiovascular risk reduction message Letter with a travel vaccination benefit message

Conditions

  • Stroke
  • Influenza Human
  • Influenza Vaccines
  • Health Behavior Change
  • Travel-Related Illness

Interventions

BEHAVIORAL

Behavioural Nudge (Influenza Risk Reduction)

A behavioural nudge via mailed letter that discusses the benefits of the influenza vaccine in preventing influenza infection and reducing cardiovascular risk.

BEHAVIORAL

Behavioural Nudge (Travel Vaccination Benefit)

A behavioural nudge via mailed letter that discusses the benefits of travel vaccines in preventing travel-related illnesses.

Sponsors & Collaborators

  • Alberta Health services

    collaborator OTHER

  • Mint Health + Drugs

    collaborator UNKNOWN

  • University of Calgary

    lead OTHER

Principal Investigators

  • Amity Quinn · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-06
Primary Completion
2026-09-01
Completion
2026-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07161739 on ClinicalTrials.gov